<DOC>
	<DOCNO>NCT02364089</DOCNO>
	<brief_summary>The general objective evaluate consequence surgical removal SCSI hypertension cardiovascular risk factor order determine evidence-based basis surgical excision SCSI preferable intensive medical regimen patient hypertension .</brief_summary>
	<brief_title>Surgery Subclinical Cortisol Secreting Adrenal Incidentalomas</brief_title>
	<detailed_description>Adrenal incidentalomas unsuspected adrenal mass find abdominal imaging . With widespread use compute tomography MRI , adrenal incidentalomas find approximately 2 % patient . In endocrinology setting , majority mass benign adenomas adrenal cortex . Approximately 10 % adenomas display little excess cortisol secretion associate degree secretory autonomy insufficient generate overt Cushing 's syndrome ( `` Subclinical Secreting Cortisol incidentalomas '' SCSI ) . However , hypertension lesser degree obesity impair glucose tolerance frequent amongst patient SCSI . The hypothesis mild hypercortisolism associate SCSI responsible clinical consequence substantiate study describe improvement resection SCSI . However , study retrospective , uncontrolled suffer imprecision numerous methodological bias . Thus , whether surgery beneficial medical treatment currently unknown consensus appropriate treatment SCSI . Patient selection Run-In period . Discontinuation previous antihypertensive treatment prescription standardize anti-hypertensive drug regimen ( SAHR ) . Monthly Blood Pressure ( BP ) measurement use home BP monitoring . The duration Run-In period ≤ 6 month end BP control SAHR two consecutive visit . End RI Second endocrine assessment eligibility Randomization ( Ra ) : 24h Ambulatory BP measurement , anthropometric metabolic evaluation . Quality life cognition questionnaire . Randomization 2 group : Gr 1 Treatment group : Surgery follow intensive medical care ; Gr 2 : Control Group : intensive medical care . Ra + 1Mo : Surgery Group 1 Ra + 2.5 Mo Ra + 13 Mo : 6 week interval follow-up Evaluation home BP monitoring adaptation SAHR . A step step reduction SAHR attempt two patient group Ra+2.5Mo . A second attempt systematically perform group Ra+8.5 Medical evaluation associate metabolic condition ( obesity , diabetes , dyslipidemia ) adaptation treatment Record medical event side effect treatment Ra + 13Mo : Final evaluation . Endocrine assessment . 24h Ambulatory BP measurement , anthropometric metabolic evaluation . Quality life cognition questionnaire .</detailed_description>
	<mesh_term>Adrenocortical Adenoma</mesh_term>
	<mesh_term>Adrenal Gland Neoplasms</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Age ≤ 80 year . Incidentally discovered unilateral SCSI : Adrenocortical tumor CT ( spontaneous density &lt; 20 HU and/or relative washout &gt; 40 % , absolute washout &gt; 60 % ) &gt; 2 cm size . Impaired DST ( cortisol &gt; 138 nmol/L 5 µg/dL ) OR • Impaired DST ( cortisol &gt; 50 83 nmol/L 1,8 3 µg/dL ) AND one biological abnormality corticotropic axis study entry : 8 a.m. plasma ACTH &lt; 2.2 pmol/L ( 10 pg/ml ) , In case ACTH 8 a.m. 10 20 pg/mL ( 2.2 4.4 pmol/L ) , peak ACTH &lt; 30 pg/mL ( 6.6 pmol/L ) CRH test midnight cortisol &gt; 150 nmol/L ( 5.4 µg/dL ) elevate lateevening salivary cortisol accord range assay increase 24hour free urinary cortisol &lt; 2.0fold laboratory upper normal limit . Systolic diastolic hypertension treat OR Systolic diastolic hypertension ( &gt; 135/85 mmHg ) treat assessed standard blood pressure selfmeasurement device . Written inform consent sign patient investigator Age &gt; 80 year . Bilateral incidentaloma . Incidentally adrenocortical tumor &lt; 2 cm History myocardial infarction , pulmonary edema stroke previous year Malignant hypertension ( &gt; 175115 mm Hg selfmeasurement ) Betablocker treatment suspend . Free urinary cortisol &gt; 2.0fold upper normal limit 08h00 plasma ACTH concentration &gt; 4.4 pmol/L ( 20 pg/ml ) Chronic renal insufficiency ( clearance &lt; 30 mL/min ) Exogenous corticosteroid treatment general local route ( inhale , eye ear drop , ophthalmic ointment , topical skin application , ear infiltration ) 6 month trial OR • Need Corticosteroid treatment OR • Medication interfere dexamethasone metabolism . ( 54 ) Pregnancy Lifethreatening pathology ( short term ) Contraindications surgery Lack control blood pressure end RunIn period Dissipation biological endocrine criterion SCSI end RunIn period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Adrenal Incidentaloma</keyword>
	<keyword>Subclinical Cushing 's syndrome</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Cardiovascular Risk Factors</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Surgery adrenal tumor</keyword>
</DOC>